Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xynomic Files Three China INDs for Lead Oncology Candidate

publication date: Dec 27, 2018

Xynomic, a clinical stage Delaware-Shanghai pharma, has filed three China INDs for its lead candidate, abexinostat, a novel HDAC inhibitor. The potentially pivotal trials will test abexinostat, a China Category 1 drug, against renal cell carcinoma and lymphoma. Abexinostat is already in a global Phase III trial, paired with pazopanib, as a first- or second-line therapy for metastatic renal cell carcinoma. Xynonic is an in-licensing company that is developing drugs for China and the US. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital